Research
Hormonal
Incretin-based therapies, including GLP-1 and GIP, enhance insulin secretion from pancreatic beta cells.
Practitioners can consider incretin-based therapies as a viable option for enhancing insulin secretion in diabetes management.
StrongSupportsmedium confidence
glucagon-like peptide-1, and glucose-dependent insulinotropic polypeptides are released from the gastrointestinal (GI) tract and act on beta cells of pancreatic islets by increasing the secretion of insulin.
Why this rating
The claim is based on established physiological mechanisms.
Source
Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology
Bhaskar Pal et al. · Journal of Diabetology · 2024
DOI 10.4103/jod.jod_117_23
reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →